Corvus Pharmaceuticals, Inc.(CRVS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Corvus Pharmaceuticals, Inc. (CRVS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CRVS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Corvus Pharmaceuticals, Inc. reports net income of $-18.0M, free cash flow of $-16.0M. Top institutional holders of CRVS by reported 13-F value include ORBIMED ADVISORS, BlackRock, STATE STREET, based on the most recent SEC filings. CRVS trades on the Nasdaq exchange and files with the SEC under CIK 1626971. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Corvus Pharmaceuticals, Inc. directly from SEC EDGAR.